InDex Pharma decimated on stop of cobitolimod Phase III program

22 November 2023

Swedish immunology company InDex Pharmaceuticals Pharmaceuticals (STO: INDEX) plunged 60% to 0.26 kronor this morning, as it reported a failed clinical trial for its ulcerative colitis candidate cobitolimod.

InDex explained that an independent data monitoring committee (DMC) independent data monitoring committee (DMC) had advised that the Phase III program CONCLUDE for cobitolimod is unlikely to meet the primary endpoint upon completion of Induction Study 1 and advised stopping the trial. The advice to discontinue the study was not based on any safety concerns, the company said.

Confirms the complexity of the disease

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK